Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

The coronavirus disease 2019 (COVID-19) pandemic has prompted significant changes in patient care in rheumatology and gastroenterology, with clinical guidance issued to manage ongoing therapy while minimising the risk of nosocomial infection for patients and healthcare professionals (HCPs). Subcutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Stefan, Ben-Horin, Shomron, Alten, Rieke, Westhovens, René, Peyrin-Biroulet, Laurent, Danese, Silvio, Hibi, Toshifumi, Takeuchi, Ken, Magro, Fernando, An, Yoorim, Kim, Dong-Hyeon, Yoon, SangWook, Reinisch, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731678/
https://www.ncbi.nlm.nih.gov/pubmed/34988877
http://dx.doi.org/10.1007/s12325-021-01990-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731678/
https://www.ncbi.nlm.nih.gov/pubmed/34988877
http://dx.doi.org/10.1007/s12325-021-01990-6

Ejemplares similares